Cart
sales@molnova.com
2'-Deoxyadenosine
CAS No. 958-09-8
2'-Deoxyadenosine( NSC 141848 | NSC141848 | NSC-141848 )
Catalog No. M27218 CAS No. 958-09-8
2'-Deoxyadenosine is the DNA nucleoside A. It pairs with deoxythymidine (T) in double-stranded DNA.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | 36 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 51 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name2'-Deoxyadenosine
-
NoteResearch use only, not for human use.
-
Brief Description2'-Deoxyadenosine is the DNA nucleoside A. It pairs with deoxythymidine (T) in double-stranded DNA.
-
Description2'-Deoxyadenosine is the DNA nucleoside A. It pairs with deoxythymidine (T) in double-stranded DNA.
-
In Vitro——
-
In Vivo——
-
SynonymsNSC 141848 | NSC141848 | NSC-141848
-
PathwayProteasome/Ubiquitin
-
TargetEndogenous Metabolite
-
RecptorPD-1/PD-L1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number958-09-8
-
Formula Weight251.246
-
Molecular FormulaC10H13N5O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (398.03 mM)
-
SMILESNc1ncnc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Yiqiang OuYang, et al. Design, Synthesis, and Evaluation of o-(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy In Vivo. J Med Chem. 2021 May 26.
molnova catalog
related products
-
Alanylphenylalanine
Alanylphenylalanine (Ala-phe) is a compound isolated from the brainstem of calves.
-
Norgestimate metabol...
Norelgestromin is one of the active metabolites of norgestimate.It is a steroidal progestin used in contraceptive patches, where it is combined with the estrogen ethinyl estradiol.
-
Dihydrodaidzein
Dihydrodaidzein-producing bacteria might lead to clarification of some of the mechanisms regulating the production of equol by fecal microbiota.
